Steven Cassar

Steven Cassar

Auto-generated profile, based on publicly available information

Steven Cassar

Preclinical Safety , AbbVie , North Chicago , Illinois 60064 , United States

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2019 in Chemical Research in Toxicology
Verified
Journal Article
Open access
SCSteven Cassar
Steven Cassar
IAIsaac Adatto
Isaac Adatto
Jennifer FreemanJennifer Freeman
Jennifer Freeman
JGJoshua T. Gamse
Joshua T. Gamse
IIIñaki Iturria
Iñaki Iturria
LZLeonard I. Zon
Leonard I. Zon
Unpredicted human safety events in clinical trials for new drugs are costly in terms of human health and money. The drug discovery industry attempts to minimize those events with diligent preclinical safety testing. Current standard practices are good at preventing toxic compounds from being tested in the clinic; however, false negative preclinical toxicity results are still a reality. Continual improvement must be pursued in the preclinical realm. Higher-quality therapies can be brought forward with more information about potential toxicities and associated mechanisms. The zebrafish model is a bridge between in vitro assays and mammalian in vivo studies. This model is powerful in its breadth of application and tractability for research. In the past two decades, our understanding of disease biology and drug toxicity has grown significantly owing to thousands of studies on this tiny vertebrate. This Review summarizes challenges and strengths of the model, discusses the 3Rs value that it can deliver, highlights translatable and untranslatable biology, and brings together reports from recent studies with zebrafish focusing on new drug discovery toxicology.